Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas M Pajewski

Showing results (121-130 of 160) with videos related to

Pageof 16
Sort By:
The Clinical Neuropsychologist|September 2, 2021
Robust demographically-adjusted normative data for the Montreal Cognitive Assessment (MoCA): Results from the systolic blood pressure intervention trialBonnie C Sachs, Gordon J Chelune, Stephen R Rapp, et al.
JAMA Network Open|May 19, 2023
Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical TrialLama Ghazi, Jincheng Shen, Jian Ying, et al.
JAMA Network Open|January 28, 2022
Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive ImpairmentZachary A Marcum, Jordana B Cohen, Chong Zhang, et al.
Hypertension (Dallas, Tex. : 1979)|March 29, 2021
Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEARTBharathi Upadhya, Nicholas M Pajewski, Michael V Rocco, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|January 13, 2016
Characterizing Frailty Status in the Systolic Blood Pressure Intervention TrialNicholas M Pajewski, Jeff D Williamson, William B Applegate, et al.
JAMA Internal Medicine|October 12, 2020
Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical PracticePaul E Drawz, Anil Agarwal, Jamie P Dwyer, et al.
Contemporary Clinical Trials|April 2, 2023
Concordance between clinical outcomes in the Systolic Blood Pressure Intervention Trial and in the electronic health recordChi D Chu, Kristin M Lenoir, Nayanjot Kaur Rai, et al.
JAMA Network Open|July 14, 2022
Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT)Jordana B Cohen, Zachary A Marcum, Chong Zhang, et al.
Contemporary Clinical Trials|January 10, 2026
The long-term effectiveness of the anti-obesity medication phentermine (LEAP) trial: Rationale, design, and baseline characteristicsCaroline Blackwell Young, Emily Rives, Kimberly A Gudzune, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 20, 2021
Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and StructureManjula Kurella Tamura, Sarah Gaussoin, Nicholas M Pajewski, et al.
Pageof 16

Showing results (121-130 of 160) with videos related to

Sort By:
Pageof 16
The Clinical Neuropsychologist|September 2, 2021
Robust demographically-adjusted normative data for the Montreal Cognitive Assessment (MoCA): Results from the systolic blood pressure intervention trialBonnie C Sachs, Gordon J Chelune, Stephen R Rapp, et al.
JAMA Network Open|May 19, 2023
Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical TrialLama Ghazi, Jincheng Shen, Jian Ying, et al.
JAMA Network Open|January 28, 2022
Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive ImpairmentZachary A Marcum, Jordana B Cohen, Chong Zhang, et al.
Hypertension (Dallas, Tex. : 1979)|March 29, 2021
Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEARTBharathi Upadhya, Nicholas M Pajewski, Michael V Rocco, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|January 13, 2016
Characterizing Frailty Status in the Systolic Blood Pressure Intervention TrialNicholas M Pajewski, Jeff D Williamson, William B Applegate, et al.
JAMA Internal Medicine|October 12, 2020
Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical PracticePaul E Drawz, Anil Agarwal, Jamie P Dwyer, et al.
Contemporary Clinical Trials|April 2, 2023
Concordance between clinical outcomes in the Systolic Blood Pressure Intervention Trial and in the electronic health recordChi D Chu, Kristin M Lenoir, Nayanjot Kaur Rai, et al.
JAMA Network Open|July 14, 2022
Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data From the Systolic Blood Pressure Intervention Trial (SPRINT)Jordana B Cohen, Zachary A Marcum, Chong Zhang, et al.
Contemporary Clinical Trials|January 10, 2026
The long-term effectiveness of the anti-obesity medication phentermine (LEAP) trial: Rationale, design, and baseline characteristicsCaroline Blackwell Young, Emily Rives, Kimberly A Gudzune, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 20, 2021
Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and StructureManjula Kurella Tamura, Sarah Gaussoin, Nicholas M Pajewski, et al.
Pageof 16